NewEdge Advisors’s BeOne Medicines Ltd ONC Stock Holding History

NewEdge Advisors’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$318K	Sell	1,117 -73	-6%	-$21.5K	﹤0.01%	2448
2026 Q1	$353K	Sell	1,190 -675	-36%	-$218K	﹤0.01%	2230
2025 Q4	$566K	Buy	1,865 +9	+0.5%	+$2.95K	﹤0.01%	1880
2025 Q3	$632K	Buy	1,856 +304	+20%	+$92.3K	﹤0.01%	1679
2025 Q2	$376K	Buy	1,552 +379	+32%	+$92.9K	﹤0.01%	1874
2025 Q1	$319K	Buy	1,173 +1,172	+117,200%	+$274K	﹤0.01%	1860
2024 Q4	$109	Hold	1	–	–	﹤0.01%	3776
2024 Q3	$132	Hold	1	–	–	﹤0.01%	3708
2024 Q2	$84	Sell	1 -7	-88%	-$1.08K	﹤0.01%	3695
2024 Q1	$1.19K	Sell	8 -97	-92%	-$15.6K	﹤0.01%	3467
2023 Q4	$18.9K	Hold	105	–	–	﹤0.01%	2585
2023 Q3	$18.8K	Sell	105 -395	-79%	-$78.2K	﹤0.01%	2396
2023 Q2	$89.1K	Buy	500 +25	+5%	+$5.76K	﹤0.01%	1887
2023 Q1	$102K	Sell	475 -80	-14%	-$19.2K	﹤0.01%	1748
2022 Q4	$6.71K	Buy	+555	New	+$102K	﹤0.01%	2492

Other funds holding ONC

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

NewEdge Advisors's ONC Position: Q2 2026 in Review

NewEdge Advisors reduced its BeOne Medicines Ltd (ONC) stake by 6.1% in Q2 2026, selling an estimated $21.5K and leaving 1,117 shares worth $318K. The position accounts for ﹤0.01% of the portfolio, ranked #2448.

NewEdge Advisors first reported a position in ONC in Q4 2022 and has held it in 15 quarters since. The position peaked at $632K in Q3 2025. 282 funds tracked by Wall St. Rank hold ONC as of Q2 2026.

NewEdge Advisors held 1,117 shares of BeOne Medicines Ltd worth $318K as of Q2 2026.
NewEdge Advisors sold 73 BeOne Medicines Ltd shares in Q2 2026, an estimated $21.5K.
BeOne Medicines Ltd made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2448 holding.
NewEdge Advisors first reported a position in BeOne Medicines Ltd in Q4 2022 and has held it in 15 quarters since.
NewEdge Advisors's BeOne Medicines Ltd position peaked at $632K in Q3 2025.
282 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.